天主教聖馬爾定醫院

胃癌化療處方集

最初出版日期：99.01
最後更新日期：115.02

癌症類別	胃癌
CCRT	(1) Cisplatin 60 mg/m^2 (N/S 500 c.c.; ≥ 4hrs) + Epirubicin 50mg/m^2 (N/S 100 c.c. 30 mins) + 5-FU 1500 mg/m^2 (N/S 500 c.c.; ≥ 4hrs)+ Leucovorin 200 m (N/S 500 c.c.; ≥ 4hrs) q4wks (Proc. ASCO 1995; 14:197) **or** (A) ↔ (B) q2wks { (A) Cisplatin 60 mg/m^2 + 5-FU 1000 mg/m^2 (N/S 500 c.c.; ≥ 4hrs) + Leucovorin 100 m (N/S 500 c.c.; ≥ 4hrs) { (B) Epirubicin 50mg/m^2 + 5-FU 1000 mg/m^2 + Leucovorin 100 mg/m^2 (2) Cisplatin 60 mg/m^2 + 5-FU 2000 mg/m^2 (N/S 500 c.c.; ≥ 4hrs) + Leucovorin 200 mg (N/S 500 c.c.; ≥ 4hrs) (Hepatogastroenterology 45(25), 594-600 Jan-Feb 1999)
Neoadjuvant	(1) Cisplatin 60 mg/m^2 (N/S 500 c.c.; ≥ 4hrs) + Epirubicin 50mg/m^2 (N/S 100 c.c. 30 mins) + 5-FU 1500 mg/m^2 (N/S 500 c.c.; ≥ 4hrs)+ Leucovorin 200 m (N/S 500 c.c.; ≥ 4hrs) q4wks (Proc. ASCO 1995; 14:197) **or** (A) ↔ (B) q2wks { (A) Cisplatin 60 mg/m^2 + 5-FU 1000 mg/m^2 (N/S 500 c.c.; ≥ 4hrs) + Leucovorin 100 m (N/S 500 c.c.; ≥ 4hrs) { (B) Epirubicin 50mg/m^2 + 5-FU 1000 mg/m^2 + Leucovorin 100 mg/m^2 (2) Cisplatin 60 mg/m^2 + 5-FU 2000 mg/m^2 (N/S 500 c.c.; ≥ 4hrs) + Leucovorin 200 mg (N/S 500 c.c.; ≥ 4hrs) (Hepatogastroenterology 45(25), 594-600 Jan-Feb 1999) (3) Oxaliplatin 85 mg/m^2 (D5W 500 c.c.; ≥ 3 hrs) q2wks + Capecitabine 1250-1500 mg/m^2/d. (2:1 or 5:2) (for metastatic or locally advanced disease) (Br J Cancer 2006 Apr 10;94(7): 959-963) (98/2/1、98/3/1、98/7/1、102/9/1、102/12/1、109/12/1 健保條例 9.10 規範；for advanced stage IIB、IIIA、IIIB、IIIC、IV) (4) Docetaxel 60,75mg/ m^2 (N/S 100 c.c.; 1hr) q 4wks or 35,40 mg/m^2 (N/S 100 c.c.; 1hr) q 2 wks (JCO, Nov. 2006 4991-4997) (108/1/1 健保條例 9.3 規範；for advanced stage IIB、IIIA、IIIB、IIIC、IV；E-G junction adenocarcinoma≥ IIB included) (5) Cisplatin(劑量同上)＋Docetaxel(劑量同上)(108/1/1 健保條例 9.3 規範；for advanced stage IIB、IIIA、IIIB、

	IIIC、IV；E-G junction adenocarcinoma ≥ IIB included) ◎〔 UFUR 900-1100 mg/m^2/d + Leucovorin 30 mg/d 〕 or 〔 Capecitabine 1250-1500 mg/m^2/d (2:1 or 5:2) 〕 **or** 〔 v. 5-FU/LV 〕 可互相取代，但需在健保條例規範之下(否則需注意自費之問題)
Adjuvant	**For stage ≧ IB~IIA，only：** (1) Cisplatin 60 mg/m^2 (N/S 500 c.c.; ≥ 4hrs) + Epirubicin 50mg/m^2 (N/S 100 c.c. 30 mins) + 5-FU 1500 mg/m^2 (N/S 500 c.c.; ≥ 4hrs)+ Leucovorin 200 m (N/S 500 c.c.; ≥ 4hrs) q4wks VI (Proc. ASCO 1995; 14:197) **or** (A) ↔ (B) q2wks VI { (A) Cisplatin 60 mg/m^2 + 5-FU 1000 mg/m^2 (N/S 500 c.c.; ≥ 4hrs) + Leucovorin 100 m (N/S 500 c.c.; ≥ 4hrs) (B) Epirubicin 50mg/m^2 + 5-FU 1000 mg/m^2 + Leucovorin 100 mg/m^2 (2) Cisplatin 60 mg/m^2 + 5-FU 2000 mg/m^2 (N/S 500 c.c.; ≥ 4hrs) + Leucovorin 200 mg (N/S 500 c.c.; ≥ 4hrs) VI (Hepatogastroenterology 45(25), 594-600 Jan-Feb 1999) **For stage ≧ IIB~IIIC (E-G junction adenocarcinoma ≥ IIB included)，only：** (1) Cisplatin 60 mg/m^2 (N/S 500 c.c.; ≥ 4hrs) + Epirubicin 50mg/m^2 (N/S 100 c.c. 30 mins) + 5-FU 1500 mg/m^2 (N/S 500 c.c.; ≥ 4hrs)+ Leucovorin 200 m (N/S 500 c.c.; ≥ 4hrs) q4wks VI (Proc. ASCO 1995; 14:197) or (A) ↔ (B) q2wks VI { (A) Cisplatin 60 mg/m^2 + 5-FU 1000 mg/m^2 (N/S 500 c.c.; ≥ 4hrs) + Leucovorin 100 m (N/S 500 c.c.; ≥ 4hrs) (B) Epirubicin 50mg/m^2 + 5-FU 1000 mg/m^2 + Leucovorin 100 mg/m^2 (2) Cisplatin 60 mg/m^2 + 5-FU 2000 mg/m^2 (N/S 500 c.c.; ≥ 4hrs) + Leucovorin 200 mg (N/S 500 c.c.; ≥ 4hrs) VI (Hepatogastroenterology 45(25), 594-600 Jan-Feb 1999) (3)Oxaliplatin 85 mg/m^2 (D5W 500 c.c.; ≥ 3 hrs) q2wks + Capecitabine 1250-1500 mg/m^2/d. (2:1 or 5:2) x 12 doses (Br J Cancer 2006 Apr 10;94(7): 959-963)(98/2/1、98/3/1、98/7/1、102/9/1、102/12/1、109/12/1 健保條例 9.10 規範；for advanced stage IIB、IIIA、IIIB、IIIC) (4) Docetaxel 60,75mg/ m^2 (N/S 100 c.c.; 1hr) q 4wks or 35,40 mg/m^2 (N/S 100 c.c.; 1hr) q 2 wks VI (JCO, Nov. 2006 4991-4997)(108/1/1 健保條例 9.3 規範；for advanced stage IIB、IIIA、IIIB、IIIC；E-G junction adenocarcinoma ≥ IIB included) (5) Cisplatin(劑量同上)＋Docetaxel(劑量同上) VI (108/1/1 健保條例 9.3 規範；for advanced stage IIB、IIIA、

	IIIB、IIIC；E-G junction adenocarcinoma ≥ IIB included) (6) Tegafur & Gimeracil & Oteracil TS-1(2:1) : 1-yr adjuvant only for stage II、IIIA、IIIB BSA : < 1.25 m^2 : 40 mg bid； BSA : 1.25-1.5 m^2 : 50 mg bid； BSA : ≥ 1.5 m^2 : 60 mg bid； (JCO, May 2009 4511-4511) ◎〔 UFUR 900-1100 mg/m^2/d + Leucovorin 30 mg/d 〕 **or** 〔 Capecitabine 1250-1500 mg/m^2/d (2:1 or 5:2) 〕 **or** 〔 v. 5-FU/LV 〕 可互相取代，但需在健保條例規範之下(否則需注意自費之問題)
Palliative	(1) Cisplatin 60 mg/m^2 (N/S 500 c.c.; ≥ 4hrs) + Epirubicin 50mg/m^2 (N/S 100 c.c. 30 mins) + 5-FU 1500 mg/m^2 (N/S 500 c.c.; ≥ 4hrs)+ Leucovorin 200 m (N/S 500 c.c.; ≥ 4hrs) q4wks (Proc. ASCO 1995; 14:197) **or** (A) ↔ (B) q2wks {(A) Cisplatin 60 mg/m^2 + 5-FU 1000 mg/m^2 (N/S 500 c.c.; ≥ 4hrs) + Leucovorin 100 mg (N/S 500 c.c.; ≥ 4hrs) (B) Epirubicin 50mg/m^2 + 5-FU 1000 mg/m^2 + Leucovorin 100 mg/m^2 (2) Cisplatin 60 mg/m^2 + 5-FU 2000 mg/m^2 (N/S 500 c.c.; ≥ 4hrs) + Leucovorin 200 mg (N/S 500 c.c.; ≥ 4hrs) (Hepatogastroenterology 45(25), 594-600 Jan-Feb 1999) (3) Oxaliplatin 85 mg/m^2 (D5W 500 c.c.; ≥ 3 hrs) q2wks + Capecitabine 1250-1500 mg/m^2/d. (2:1 or 5:2) or 5-FU or UFUR(Br J Cancer 2006 Apr 10;94(7): 959-963) (4) Docetaxel 60,75mg/ m^2 (N/S 100 c.c.; 1hr) q 4wks or 35,40 mg/m^2 (N/S 100 c.c.; 1hr) q 2 wks (JCO, Nov. 2006 4991-4997)(108/1/1 健保條例 9.3 規範；for advanced stage IIB、IIIA、IIIB、IIIC、IV；E-G junction adenocarcinoma ≥ IIB included) (5) Cisplatin(劑量同上)＋Docetaxel(劑量同上)(108/1/1 健保條例 9.3 規範；for advanced stage IIB、IIIA、IIIB、IIIC、IV；E-G junction adenocarcinoma ≥ IIB included) (6) Paclitaxel 135mg/m^2 (N/S 500 c.c.; 3 hrs) q4wks (or 85 mg/m^2 (N/S 300 c.c.; 2hrs) q2wks) (Br J Cancer 2000 Jul; 83(4):458-462) (亦可與 5-FU (UFUR or Capecitabine) 併用) (7) UFUR+LV or v. 5-FU+LV (8) Nivolumab 240mg + Oxaliplatin +5-FU or Capecitabine (+ Taxotere in E-G J)(113/04/1 健保條例 9.10) (9) Trastruzumab (Herceptin)(限 I.V.) + Cisplatin 60 mg/m^2 + 5-FU 2000 mg/m^2 + Leucovorin 100 mg or

	Capecitabine 1250-1500 mg/m^2/d (2:1 or 5:2)(+ Taxotere in E-G J)(109/2/1 健保條例 9.18) (10) Lonsurf 35mg/m^2 BID on D1-D5 , D8-D12 q 4 wks/cycle(109/12/1 健保條例 9.66) ◎〔 UFUR 900-1100 mg/m^2/d + Leucovorin 30 mg/d 〕 or 〔 Capecitabine 1250-1500 mg/m^2/d (2:1 or 5:2) 〕 or 〔 v. 5-FU/LV 〕 可互相取代，但需在健保條例規範之下(否則需注意自費之問題) ◎亦可考慮下例藥物： * MMC 8mg / m^2 (N/S 100 c.c.; 30 mins) q 4 wks (Br J Cancer 2002 Jan21; 86(2):213-217) * Irinotecan 140,150,160 mg/ m^2 (N/S 500 c.c.; 3 hrs) q2 wks (Oncology Dec. 1, 2000) * Pemetrexed 500mg/ m^2 (N/S 100 c.c.; 20 mins) q 4wks (Clinical Cancer Research Jun 2004 Vol.10 Issue12)

Immunotherapy: PD-1, PD-L1 抑制劑(如 atezolizumab、nivolumab、Pembrolizumab、ipilimumab；durvalumab；tremelimumab)(109/06/01 健保條例)